Ethics approval and consent to participate
The study protocol and all amendments were reviewed by the independent ethics committee or institutional review board for each center. The study was conducted according to ICH E6 Guideline for Good Clinical Practice that have their origin in the Declaration of Helsinki. Informed consent was obtained from each patient in writing before any study-specific procedure was performed.
Consent for publication
All authors give consent for the publication of the manuscript in Journal of Experimental & Clinical Cancer Research.
S. L. Chan: Research fund from Bayer, Eisai, Ipsen, MSD, Sirtex; advisors for AstraZeneca, BMS, Eisai, Novartis, MSD.
M. Schuler: Consultant (compensated) for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Novartis, Roche, Takeda; honoraria for CME presentations from Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, MSD, Novartis; research funding to institution from AstraZeneca, Boehringer Ingelheim, Bristol Myers-Squibb, Novartis.
Y.-K Kang: Consulting fee from ALX Oncology, Amgen, Blueprint, BMS, Daehwa, MacroGenics, Merck, Novartis, Roche, Surface Oncology, Zymeworks.
C.-J Yen: No conflicts of interest to declare.
J. Edeline: Consultancy/honoraria from AstraZeneca, Bayer, BMS, Boston Scientific, Eisai, Ipsen, MSD, Roche; grant funding from BeiGene, BMS, Boston Scientific.
S.P. Choo: Consultancy/honoraria from Bayer, BMS, Eisai, Ipsen, MSD, Roche; Speaker fees from BMS, Eisai, Eli Lilly, Roche, Sirtex; grant funding from BMS, Sirtex.
C.-C. Lin: Consulting fee from AbbVie, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Novartis; honoraria from Eli Lilly, Novartis, Roche; support for attending meeting or travel from BeiGene, Daiichi Sankyo, and Eli Lilly.
T. Okusaka: Grant and honoraria from Novartis.
K.-H. Weiss: grants from Alexion, Novartis, Orphalan, Univar; consulting fee from Alexion, Bayer, Chiesi, Orphalan, Pfizer, Ultragenyx, Univar, Vivet therapeutics; honoraria from Falk; support for attending meeting from AbbVie, Bayer, Gilead.
T. Macarulla: Consultancy/advisory role with Amgen, Baxter, Celgene, Incyte, Q&D Therapeutics, Servier, Shire; research funding from AstraZeneca, BeiGene, Celgene.
S. Cattan: grants, consulting fee and honoraria from AstraZeneca, Bayer, Ipsen, Roche; payment for expert testimony and support for travel from AstraZeneca, Ipsen, Roche; participation in advisory board for Roche.
J.-F. Blanc: honoraria from Bayer, Ipsen, Roche; support for attending meeting/travel from Bayer and Ipsen; participation in safety/advisory board for AstraZeneca, Bayer, BMS, Eisai, Ipsen, Eli Lilly, MSD, Roche.
K.-H Lee: honoraria from AstraZeneca and Roche; participated in advisory board for Surface Oncology.
M. Maur: No conflicts of interest to declare.
S. Pant: Consulting or advisory role for 4D Pharma, Ipsen, Xencor, Zymeworks; research funding from 4D Pharma, Arcus Biosciences, ArQule, Astellas Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Elicio Therapeutics, Five Prime Therapeutics, GlaxoSmithKline, Ipsen, Janssen, Lilly, Mirati Therapeutics, NGM Biopharmaceuticals, Novartis, Onco Response, Purple Biotech, RedHill Biopharma, Rgenix, Sanofi/Aventis, Xencor.
M. Kudo: Consulting fee from BMS, Eisai, MSD, Ono Pharmaceuticals, Roche; honoraria from Bayer, BMS, Chugai, EA Pharma, Eisai, Eli Lilly, MSD; Research funding from AbbVie, Chugai, Eisai, EA Pharma, Gilead Sciences, Ono Pharmaceutical Co, Otsuka, Sumitomo Dainippon Pharma, Taiho, Takeda.
E. Assenat: No conflicts of interest to declare.
A.X. Zhu: Consulting fee from Bayer, BMS, Eisai, Eli Lilly, Exelixis, Roche, Sanofi.
T. Yau: Consulting or advisory role and honoraria from AbbVie, AstraZeneca, Bayer, Bristol Myers-Squibb, Eisai, Eli Lilly, EMD Serono, Exelixis, H3 Biomedicine, Ipsen, MSD, New B Innovation, Novartis, OrigiMed, Pfizer, SillaJen, Sirtex, Taiho.
H.Y. Lim: Participation on data safety monitoring committee or advisory board from Bayer, BMS, Eisai, Merck Serono and Roche.
J. Bruix: Consultancy from AbbVie, Adaptimmune, ArQule, Astra-Medimmune, Basilea, Bayer Shering Pharma, Bio-Alliance, BMS, BTG, Eisai, Gilead, Incyte, Ipsen, Kowa, Lilly, MSD, Nerviano, Novartis, Polaris, Quirem, Roche, Sirtex, Sanofi, Terumo; Research grants from Bayer, Ipsen; Educational grants from Bayer; Paid conferences from Bayer, BTG and Ipsen; Paid talks for Bayer Shering Pharma, BTG Biocompatibles, Eisai, Ipsen Sirtex, Terumo.
A. Geier: Advisor and Steering Committee member for AbbVie, Alexion, Bayer, BMS, Eisai, Gilead, Intercept, Ipsen, Novartis, Pfizer, Roche, Sanofi-Aventis, Sequana; Speaker fees from AbbVie, Alexion, BMS, CSL Behring, Falk, Gilead, Intercept, Merz, Novartis, Roche, Sequana; Research support from Intercept and Falk (NAFLD CSG), Novartis.
C. Guillén-Ponce: Registration for continuing education courses and congresses by Astra Zeneca, Merck Serono and Sanofi.
A. Fasolo: No conflicts of interest to declare.
R.S. Finn: Grants from Adaptimmune, Bayer, BMS, Eisai, Eli Lilly, Merck, Pfizer, Roche/Genentech; consulting fee from Adaptimmune, AstraZeneca, Bayer, BMS, CStone, Eisai, Eli Lilly, Merck, Pfizer, Roche/ Genentech.
J. Fan: No conflicts of interest to declare.
A. Vogel: consulting fee from Amgen, AstraZeneca, Bayer, BMS, BTG, EISAI, GSK, Incyte, Ipsen, Lilly, Merck, PierreFabre, MSD, Novartis, Roche, Sanofi, Servier, Sirtex, Terumo,; honoraria from Amgen, AstraZeneca, Bayer, BMS, BTG, EISAI, GSK, Incyte, Ipsen, Lilly, Merck, MSD, Novartis, PierreFabre, Roche, Sanofi, Servier, Sirtex, Terumo.
S. Qin: No conflicts of interest to declare.
M. Riester: Novartis employee.
V. Katsanou: Novartis employee.
M. Chaudhari: worked for Novartis during employment at IQVIA.
T. Kakizume: Novartis employee at the time of study and manuscript writing; currently working at Takeda.
Yi Gu: Novartis employee and stock holder.
D. Graus Porta: Novartis employee and stockholder at the time of study conduct and manuscript finalization.
A. Myers: Novartis employee.
J-P. Delord: Consulting fee from BMS, MSD, Roche; honoraria from Roche; participation on data safety monitoring board or advisory board for BMS, MSD, Novartis, Transgene.